The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Original Article

Safety Profile of Using Tocilizumab in the Treatment of Severely Ill Patients with COVID-19

Authors: Michael J. Schnaus, MD, Thomas E. Schmidt, MD, Kate Schmiechen, BS, Nicole D. Garrett, PhD, Elie Gertner, MD

Abstract

Objectives: Tocilizumab, originally used in the treatment of autoimmune disorders such as rheumatoid arthritis, had its use expanded to treat hyperinflammatory changes in coronavirus disease 2019. The objective of this study was to evaluate the risk of secondary infections and gastrointestinal side effects in patients treated with tocilizumab for severe COVID-19 infection.

Methods: We performed a retrospective cohort study of 97 patients to evaluate the safety of tocilizumab use in severely ill coronavirus disease 2019 patients. Thirty patients (30.9%) were diagnosed as having a secondary infection; all of these patients required mechanical ventilation.

Results: These patients had higher 30-day mortality and longer lengths of stay compared with those without a secondary infection.

Conclusions: The results of our study suggest a degree of safety in short-term tocilizumab use and suggests that clinicians pay attention to the elevated risk of secondary infection in the patient population treated with tocilizumab and require a ventilator for respiratory support.
Posted in: Infectious Disease154

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2010;3:81–89.
 
2. Saki A, Rajaei E, Rahim F. Safety and efficacy of tocilizumab for rheumatoid arthritis: a systematic review and meta-analysis of clinical trial studies. Reumatologia 2021;59:169–179.
 
3. Preuss CV, Anjum F. Tocilizumab. In: StatPearls. NCBI Bookshelf version. StatPearls Publishing: 2024. Accessed. https://www.ncbi.nlm.nih.gov/books/NBK570644/. Accessed December 2024.
 
4. Saad E, Awadelkarim A, Agab M, et al. Tocilizumab-associated small bowel perforation in a young patient with rheumatoid arthritis: a lesson to remember during COVID-19 pandemic. J Med Cases 2022;13:135–139.
 
5. Xie F, Yun H, Bernatsky S, et al. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol 2016;68:2612–2617.
 
6. Frigault MJ, Nikiforow S, Mansour MK, et al. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood 2020;36:137–139.
 
7. Rubio-Rivas M, Corbella X, Formiga F, et al. Risk categories in COVID-19 based on degrees of inflammation: data on more than 17,000 patients from the Spanish SEMI-COVID-19 Registry. J Clin Med 2021;10:2214.
 
8. Rubio-Rivas M, Mora-Luján JM, Montero A, et al. The use of corticosteroids or tocilizumab in COVID-19 based on inflammatory markers. J Gen Intern Med 2022;37:168–175.
 
9. Crook P, Logan C, Mazzella A, et al. The impact of immunosuppressive therapy on secondary infections and antimicrobial use in COVID-19 inpatients: a retrospective cohort study. BMC Infect Dis 2023;23:808.
 
10. Klein EY, Monteforte B, Gupta A, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses 2016;10:394–403.
 
11. Shi C, Shan Q, Xia J, et al. Incidence, risk factors and mortality of invasive pulmonary aspergillosis in patients with influenza: a systematic review and meta-analysis. Mycoses 2022; 65:152–163.
 
12. Alshrefy AJ, Alwohaibi RN, Alhazzaa SA, et al. Incidence of bacterial and fungal secondary infections in COVID-19 patients admitted to the ICU. Int J Gen Med 2022;15:7475–7485.